Blisibimod

B-cell activating factor (BAFF) inhibitor for the potential treatment of B-cell associated renal diseases, including IgA nephropathy.

Learn more about Blisibimod

LATEST NEWS

Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura.

READ MORE

Anthera Pharmaceuticals to Present at 30th Annual ROTH Conference.

READ MORE